Gyre Therapeutics Inc
GYRE7.690USD
+0.150+1.99%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
698.43MMarket Cap
167.69P/E TTM
More Details of Gyre Therapeutics Inc Company
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Company Info
Ticker SymbolGYRE
Company nameGyre Therapeutics Inc
IPO dateApr 12, 2006
CEOMr. Ping Zhang
Number of employees574
Security typeOrdinary Share
Fiscal year-endApr 12
Address12770 High Bluff Drive, Suite 150
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92130
Phone16199493681
Websitehttps://www.gyretx.com/
Ticker SymbolGYRE
IPO dateApr 12, 2006
CEOMr. Ping Zhang
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board, Interim Chief Executive Officer
Executive Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dan Weng
Dr. Dan Weng
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GNI Group Ltd
80.12%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
BlackRock Institutional Trust Company, N.A.
0.84%
Other
11.52%
Shareholders
Shareholders
Proportion
GNI Group Ltd
80.12%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
BlackRock Institutional Trust Company, N.A.
0.84%
Other
11.52%
Shareholder Types
Shareholders
Proportion
Corporation
80.12%
Individual Investor
7.04%
Investment Advisor
2.47%
Investment Advisor/Hedge Fund
0.91%
Research Firm
0.31%
Pension Fund
0.06%
Bank and Trust
0.02%
Hedge Fund
0.02%
Other
9.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
124
82.04M
93.13%
+8.95M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
2023Q1
173
927.40K
37.69%
-976.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GNI Group Ltd
72.77M
82.6%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.22%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.22%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.10M
1.24%
+774.02K
+240.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
506.93K
0.58%
+12.53K
+2.53%
Mar 31, 2025
Ye (Weiguo)
700.00K
0.79%
+50.00K
+7.69%
Apr 01, 2025
Geode Capital Management, L.L.C.
312.32K
0.35%
+8.22K
+2.70%
Mar 31, 2025
SBI Securities Co., Ltd.
123.63K
0.14%
+22.39K
+22.12%
Mar 31, 2025
State Street Global Advisors (US)
128.77K
0.15%
+2.13K
+1.68%
Mar 31, 2025
Northern Trust Investments, Inc.
106.90K
0.12%
+3.52K
+3.40%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Date
Type
Ratio
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
